1. Home
  2. CBIO vs ENRD Comparison

CBIO vs ENRD Comparison

Compare CBIO & ENRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$13.97

Market Cap

537.5M

Sector

N/A

ML Signal

HOLD

Logo Einride AB American Depositary Shares

ENRD

Einride AB American Depositary Shares

N/A

Current Price

$4.15

Market Cap

560.3M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CBIO
ENRD
Founded
2003
N/A
Country
United States
Sweden
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
537.5M
560.3M
IPO Year
2013
2025

Fundamental Metrics

Financial Performance
Metric
CBIO
ENRD
Price
$13.97
$4.15
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $26.67
N/A
AVG Volume (30 Days)
★ 376.0K
153.2K
Earning Date
04-29-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $18,500.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$279.20
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.72
$3.40
52 Week High
$27.41
$10.49

Technical Indicators

Market Signals
Indicator
CBIO
ENRD
Relative Strength Index (RSI) 31.82 43.91
Support Level $9.95 $3.40
Resistance Level $18.53 $7.72
Average True Range (ATR) 1.41 0.42
MACD -0.63 0.05
Stochastic Oscillator 7.61 58.68

Price Performance

Historical Comparison
CBIO
ENRD

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About ENRD Einride AB American Depositary Shares

Einride AB is a technology company that develops and operates digital, electric, and autonomous freight solutions. Its platform includes planning and optimization tools, autonomous technologies, electric heavy-duty vehicle fleets, and charging infrastructure. It serves customers across North America, Europe, and the Middle East. The company's solutions support customers in transitioning logistics operations to electric and autonomous systems. Its business model includes Freight-Capacity-as-a-Service (FCaaS) and Software-as-a-Service (SaaS) offerings delivered through an AI-based platform that manages aspects of electric and autonomous operations.

Share on Social Networks: